A5032153972- Cannabis and Cannabinoid Research
- Cancer survivorship and care
- Pain Management and Opioid Use
- Cancer, Stress, Anesthesia, and Immune Response
- Bipolar Disorder and Treatment
- Cancer Treatment and Pharmacology
- Religion, Spirituality, and Psychology
- Prostate Cancer Treatment and Research
- Neutropenia and Cancer Infections
- Pediatric Pain Management Techniques
- Metabolism, Diabetes, and Cancer
- Pharmacological Receptor Mechanisms and Effects
- PARP inhibition in cancer therapy
- Suicide and Self-Harm Studies
- Palliative Care and End-of-Life Issues
- Homelessness and Social Issues
- Diet and metabolism studies
- Cancer-related cognitive impairment studies
- Childhood Cancer Survivors' Quality of Life
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Diabetes Treatment and Management
- Opioid Use Disorder Treatment
- Cancer Immunotherapy and Biomarkers
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
HealthPartners
2017-2025
Cancer Research Center
2020-2025
Park Nicollet Clinic
2021-2024
Park Nicollet Health Services
2014-2021
Frauenshuh Cancer Center
2016-2020
Metro-Minnesota Community Oncology Research Consortium
2020
University of Hawaii Cancer Center
2019
University of Minnesota
2012-2017
Minneapolis VA Health Care System
2013-2014
Emory University
2013
Electronic systems that facilitate patient-reported outcome (PRO) surveys for patients with cancer may detect symptoms early and prompt clinicians to intervene.To evaluate whether electronic symptom monitoring during treatment confers benefits on quality-of-life outcomes.Report of secondary outcomes from the PRO-TECT (Alliance AFT-39) cluster randomized trial in 52 US community oncology practices PRO or usual care. Between October 2017 March 2020, 1191 adults being treated metastatic were...
BACKGROUND Preclinical studies show that opioids stimulate angiogenesis and tumor progression through the mu opioid receptor (MOR). Although MOR is overexpressed in several human malignancies, effect of chronic requirement on cancer or survival has not been examined humans. METHODS We performed a retrospective analysis 113 patients identified Minneapolis VA Tumor Registry (test cohort) 480 from national Central Cancer (validation who had diagnosed with stage IV prostate between 1995 2010 to...
Minnesota's medical cannabis program is unique, in that it routinely collects patient-reported scores on symptoms. This article focuses changes symptom severity reported by patients with cancer during their first 4 months of participation.Patients symptoms (anxiety, lack appetite, depression, disturbed sleep, fatigue, nausea, pain, and vomiting) at worst over the last 24 hours before each purchase. Baseline eight were statistically compared average participation. Symptom also calculated as...
Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.In this open-label randomized phase III study, cancer were randomly assigned 1:1 ADT (300 mg oral twice daily; experimental arm) or bicalutamide (50 once control arm). The primary objective was comparison overall survival (OS), targeting...
Background: Medical cannabis has been available in the State of Minnesota since July 2015 through Cannabis Program (MMCP). Objectives: Our study aimed to delineate oncology providers' views on medical cannabis, identify barriers patient enrollment, and assess clinicians' interest a clinical trial patients with stage IV cancer. Methods: From June August 2017, we distributed 14-question survey physicians, advanced practice nurses, physician assistants who care for adults children Descriptive...
Background: We conducted a multicenter, randomized trial of early integrated palliative and oncology care in patients with advanced cancer to confirm the benefits (PC) seen prior single-center studies. Methods: randomly assigned newly diagnosed incurable (n = 195) or usual 196) at sites through Alliance for Clinical Trials Oncology. Patients intervention were expected meet PC clinician least monthly until death, whereas consulted on request. The primary endpoint was change quality life from...
Abstract Background The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access medical and recreational use. Among cancer patients, is often used to ameliorate adverse effects treatment. Data are limited on the extent type among patients during treatment perceived benefits harms. This multicenter survey was conducted assess residing in varied cannabis. Methods A total 12 NCI-Designated Cancer Centers, across...
Objectives: Pancreatic adenocarcinoma is frequently associated with pain requiring opioid therapy. Opioids, however, have been implicated in causing tumor progression, ultimately shortening survival. We examined the impact of pain, use, and mu-opioid receptor (MOP-R) expression tissue on progression-free survival overall patients metastatic pancreatic cancer. Methods: identified 103 receiving chemotherapy abstracted data from Tumor Registry, addition to exposure, carbohydrate antigen 19-9...
349527 Background: Symptoms are common during cancer care but often go undetected. Digital systems that elicit patient-reported outcomes (PRO) surveys may detect symptoms early and prompt clinicians to intervene, thereby alleviating suffering averting complications. Methods: In a cluster-randomized trial, U.S.-based community oncology practices were randomized 1:1 digital symptom monitoring with PRO surveys, or usual control. Patients receiving systemic treatment for metastatic eligible. At...
Cannabis use among individuals with cancer is best understood using survey self-report. As cannabis remains federally illegal, surveys could be subject to nonresponse and measurement issues impacting data quality. We surveyed medical for a cancer-related condition in the Minnesota Medical Program (MCP). Although responders are older, there no differences by race ethnicity, gender, or receipt of reduced registry enrollment fee. Responders made more recent purchase recently completed an...
e20631 Background: Pain is an independent prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC). In vitro and pre-clinical experiments, opioids promote angiogenesis accelerate tumor growth metastases. Opioid receptors are expressed human NSCLC. Morphine stimulates proliferation invasiveness of NSCLC lines by cross-activation EGFR other signaling pathways. Methods: To examine if long-term opioid requirement, independently chronic pain, associated with survival, we...